UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the

Entertainment leader Sphere stock continues to outperform in the current market environment, setting

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the p

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: C

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opp

Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced a call for proposals for its annual Cytokin

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01,

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of inte

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

Citigroup analyst Eric Joseph initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

Third Annual Muscle Biology-Focused Research Symposium  Highlighting Recent Innovations in the Field

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the presentation of new data reinforcing th

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

Wells Fargo analyst Yanan Zhu maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises t

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CY

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift am

Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and ra

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and ra

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst c

Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the pri

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc

Cytokinetics stock jumps after Phase 3 ACACIA-HCM trial meets endpoints, showing improved exercise p

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced positive topline results from ACACIA-HCM (A

Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern TimeSOUTH SAN FRANCISCO

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced nine presentations at the European Society

Wells Fargo analyst Yanan Zhu initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Overweight

Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the p

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises

UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and raises the pric

Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and r

Citizens analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and r

Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the pri

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which missed the analyst c